Kwak Min Ji, Irizarry-Caro Jorge A, Martinez Paola Rodriguez, Going James, Lee Jessica, Giza Dana, Amjad Nuzah, Leech Ana, Jantea Rachel, Flores Renee, Rianon Nahid, Dhoble Abhijeet
Division of Geriatric and Palliative Medicine, McGovern Medical School, TX, USA.
Department of Internal Medicine, McGovern Medical School, TX, USA.
J Geriatr Cardiol. 2025 May 28;22(5):525-533. doi: 10.26599/1671-5411.2025.05.003.
Aortic stenosis (AS) is one of the most common types of valvular heart disease in older adults, with age being significantly associated with the development of AS. The transcatheter aortic valve replacement (TAVR) procedure, since it was first performed in 2002, has emerged as a preferred treatment option for patients who are at intermediate to high surgical risk due to advanced age or medical comorbidities. Older adults with severe AS may present with acute decompensated heart failure leading to cardiogenic shock (CS). Among patients 65 years and older with AS presenting for TAVR, 4.1% were reportedly in acute CS. Regardless of etiology, mortality from CS itself is high (30%-50%) and increases with advancing age. TAVR for these patients could provide a definite treatment for both AS and CS. There is still limited evidence regarding the safety and efficacy of TAVR in this population, but recent studies are promising, with successful procedural results and a good recovery rate after the procedure. However, particularly for older adults, there are other factors that clinicians should consider during pre- and post-procedural status, such as patient's goals, frailty, polypharmacy, dementia, or delirium. In this article, we reviewed current studies regarding TAVR for older adults with AS and CS, the reason for comprehensive geriatric assessment, and the introduction of appropriate geriatric assessment tools based on the Age-Friendly 4Ms framework that cardiologists can adopt in real-world practice.
主动脉瓣狭窄(AS)是老年人中最常见的瓣膜性心脏病类型之一,年龄与AS的发生显著相关。自2002年首次开展经导管主动脉瓣置换术(TAVR)以来,该手术已成为因高龄或合并症而具有中到高手术风险患者的首选治疗方案。患有严重AS的老年人可能会出现急性失代偿性心力衰竭,进而导致心源性休克(CS)。据报道,在65岁及以上接受TAVR的AS患者中,4.1%处于急性CS状态。无论病因如何,CS本身的死亡率都很高(30%-50%),且随年龄增长而增加。对这些患者进行TAVR可为AS和CS提供确切的治疗。关于TAVR在该人群中的安全性和有效性的证据仍然有限,但近期研究前景乐观,手术结果成功,术后恢复率良好。然而,特别是对于老年人,临床医生在术前和术后状态时还应考虑其他因素,如患者目标、虚弱、多重用药、痴呆或谵妄。在本文中,我们回顾了关于TAVR治疗老年AS和CS患者的当前研究、进行全面老年医学评估的原因,以及基于心内科医生可在实际临床实践中采用的“友善老年4M”框架引入合适的老年医学评估工具。